NCT02648269View on ClinicalTrials.gov

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Gout

Interventions

DRUG

SEL-110

BIOLOGICAL

SEL-212

BIOLOGICAL

SEL-037

Trial Locations (6)

16635

Altoona Center for Clincal Research, Duncansville

21201

SNBL Clinical Pharmacology Center Inc., Baltimore

32809

Orlando Clinical Research Center, Inc., Orlando

33143

Miami Research Associates, Miami

55404

Davita Clinical Research, Minneapolis

72205

Baptist Health Center for Clinical Research, Little Rock

All Listed Sponsors

lead

Selecta Biosciences, Inc.

INDUSTRY

NCT02648269 - Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels | Biotech Hunter | Biotech Hunter